HIV NEWS
-
THE PETER SCHICK FOUNDATION HAS GOTTEN A PRE-IND APPROVAL FROM THE FDA TO STUDY BLUE GREEN ALGAE IN HIV+ PATIENTS
HIV treatment and erectile problems HIV Weekly December 9th, 2009
Who updates HIV Treatment Recommendations - Karim, MD,PHD Journal Watch Infectious Diseases
On this Worlds AIDS Days one has to reflect on one of the most important aspects of policy for the coming year
WHAT THE US NEEDS IS A NATIONAL AIDS STRATEGY
Dr. Judy Blumenthal, formerly of AMFAR, presented a talk on November 30,2009 on How the Obama administration will fight AIDS
IAAPAC'09
President Obama announces US HIV tranvel ban will end in January 2010
GSK and OPfizer launch joint HIV venture, VIIV Healthcare
IAS applauds White House Announcement of Repeal of the United States
IAS Expresses Concern over future of HIV Prevention Efforts in Russia
CD 4-cell-count below 400 increases cancer risk for patients with HIV
FDA committee recommends approval of maraviroc for first-line treatment in US
Four million now receiving Antiretroviral therapy, 6 million still in need. United Nations Agencies
Mediterranean diet Associated with Reduced Risk for depression Archives of general Psychiatry. October 6,2009
Nutritional formula linked to reduced CD 4 cell loss in untreated people From the ICAAC meeting in San Francisco
GS-9380 boosts atazanavir jsut as well as ritonavir From the ICAAC meeting in San Francisco Sept 28,2009
Tobacco, marijuana and alcohol may lower levels of some anti-HIV drugs from Inter science Conference on Anti microbial agents and Chemotherapy
Inflammation signals heart disease risk in people with HIV Journal of Clinical Infectious Disease
Deportation of migrants with HIV often contravenes human rights treaties
Reduced efavirenz dose safe and effective in patients with high blood levels of drug
The Perilous success: what if the new HIV prevention methods work?
Disclaimer
The materials posted on The Peter Schick Foundation Web site reflect the views of the reviewers or of authors of the material, not those of The Peter Schick Foundation or the organizations providing support or educational grants . The materials may discuss new treatments, uses and dosages for HIV therapeutic products that have not been approved by the United States Food and Drug Administration. Readers should verify all information and consult a qualified HIV healthcare provider about any therapeutic product or treatment discussed.
